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are becoming increasingly important, not only for refining 
the discovery of prognostic markers or therapeutic targets, 
but also for the design of prospective clinical trials. Patients 
with WNT subgroup tumours, for example, generally have 
a favourable prognosis, and may benefit from a reduction or 
omission of radiotherapy or chemotherapy to spare neuro-
logical side-effects or other toxicities, as is now being pro-
spectively tested in upcoming trials both in North America 
and Europe. In contrast, patients with poor prognosis Group 
3 tumours may benefit from intensification of up-front ther-
apy. Furthermore, many new targeted therapeutics are likely 
to be efficacious in only one subgroup, such as smoothened 
It is now clear that medulloblastoma (MB), one of the 
most clinically challenging paediatric brain tumours, is not 
a single disease entity. Rather, it comprises four distinct 
molecular subgroups (Wnt pathway activated (WNT), Sonic 
hedgehog pathway activated (SHH), and the less well-char-
acterised Group 3 and Group 4) [7, 15], which are highly 
divergent in terms of their patient demographics, underly-
ing biology, and survival outcomes [4, 6]. These subgroups 
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inhibitors for SHH pathway-driven MB [1, 2]. A phase III 
clinical trial randomising SMO inhibition against standard 
of care in relapsed SHH-MB patients will start recruiting 
in mid-late 2013. A method for accurate and robust classi-
fication into tumour subgroups that is applicable to standard 
pathology specimens is therefore of key clinical relevance.
The MB subgroups were originally defined based on 
gene expression profiling from fresh-frozen tumour material 
[7]. Whilst there are methods to apply such an RNA-based 
analysis to formalin-fixed paraffin-embedded (FFPE) mate-
rial, classification accuracy is inferior to that obtained with 
frozen tissue, particularly when analysing older samples [9]. 
Furthermore, the use of immunohistochemistry as an alter-
native subgrouping method [7] has proved difficult to stand-
ardise across multiple neuropathology laboratories. The use 
of a DNA-based platform for subgrouping has clear advan-
tages due to the superior stability of DNA compared with 
RNA. Methylation profiling has recently been applied for 
the subgrouping of large series of, for example, glioblastoma 
and chronic lymphocytic leukaemia samples [5, 10, 14]. It 
has also been proposed as being suitable for medulloblas-
toma subclassification, although the older Illumina Golden-
Gate platform assessed only a limited subset of genes, and 
a proportion of samples remained unclassifiable [12]. Also, 
whilst the concordance between methylation and expression 
reported by Schwalbe et al. was fairly good (81.5 %), some 
WNT and SHH-subgroup tumours were misclassified—a 
clinically important distinction for forthcoming trials. We 
therefore applied the Illumina Infinium HumanMethyla-
tion450 BeadChip array (450k array) to generate genome-
wide methylation profiles of a large series of medulloblas-
toma samples (see Supplementary Methods). The first cohort 
comprised 107 frozen MB samples collected within the 
ICGC PedBrain Tumor Project (Heidelberg cohort) [3]. Of 
these, 86 had matching Affymetrix U133 plus 2.0 expres-
sion array data, allowing for a direct comparison between 
the subgroup classifications of the two methods. Unsuper-
vised k-means consensus clustering on all CpG probes with 
a standard deviation >0.25 (n = 21,092) clearly indicated the 
presence of four subgroups (Fig. 1a). These methylation sub-
groups very closely recapitulated the gene expression sub-
groups of the matching tumours (95.3 % concordance, Rand 
index = 0.86, p < 0.0001; Fig. 1b, c). As expected from 
previous subgrouping studies, the discordant cases involved 
switches between Group 3 and Group 4, while the WNT and 
SHH groups were clearly distinct (Fig. 1c, d).
The 450k array is also suitable for analysis of DNA from 
FFPE material. Profiling of the same tumour from both fro-
zen and FFPE material (n = 3) showed a higher correlation 
than the maximum correlation between different donors, 
indicating the robustness of this assay for archival tissue 
(mean Pearson’s correlation for paired samples, r = 0.987, 
maximum correlation for any two unpaired samples, 
r = 0.975; Fig. 1e). We therefore profiled an independent set 
of 169 FFPE MB samples using the methylation array. These 
were confirmed as unique samples using SNP genotyping 
probes from the array platform, which allows for testing to 
detect duplicate samples from the same patient. Consensus 
clustering of these samples together with the fresh-frozen 
cohort did not show any grouping by type of material, and all 
samples could be assigned a subgroup annotation (Fig. 1f). 
Using a reduced 48–CpG signature to train a support vec-
tor machine (SVM) classifier on the frozen tissue cohort, we 
were able to predict a tumour subgroup for the FFPE sam-
ples with an extremely close match to the clustering sub-
group (97.6 % concordance, Rand index = 0.93, p < 0.0001; 
Supplementary Figure 1a, b). This signature allows for sim-
ple classification of single clinical samples without the need 
for comparison against a larger reference dataset. The data 
for these signature probes for the Heidelberg frozen tumour 
cohort are given in Supplementary Table 1.
We also investigated the impact of input DNA quantity 
on resulting data quality, using a dilution series of a single 
sample down to as little as 10 ng input material (the manu-
facturer’s recommended input is 500 ng for fresh-frozen 
material or 250 ng for FFPE DNA). For both fresh-frozen 
and FFPE DNA, there was a very high correlation between 
profiles at all input quantities down to 50 ng (Fig. 1g). The 
frozen sample was also tested with 25 and 10 ng of input, 
resulting in a slightly lower correlation. However, even at 
10 ng, the sample would still have been accurately classi-
fied as an SHH tumour (Supplementary Figure 1c). Thus, 
this platform may be suitable for molecular subgrouping 
even when DNA quantities are limiting.
To further validate the broad applicability of this tech-
nique, we examined an additional independent tumour 
cohort with matching expression subgrouping data (derived 
as previously described [8]), for which the 450k arrays 
Fig. 1  a k-means consensus clustering of the Heidelberg fresh-fro-
zen cohort (n = 107) using the 21,092 most variable CpG probes 
(SD > 0.25) indicates the presence of four major subgroups in the DNA 
methylation data. b Heatmap of DNA methylation values within the four 
subgroups derived from the consensus clustering. The gene expression 
subgroup of the matched samples is indicated below the heatmap. Eight 
normal cerebellum controls are also shown for comparison. c Concord-
ance chart of the gene expression versus DNA methylation-derived sub-
groups for each sample. d Multidimensional scaling (MDS) analysis of 
the same samples and same CpG probes used for the consensus cluster-
ing. e Correlation of DNA methylation values derived from fresh-frozen 
and FFPE material from a single tumour sample. f Heatmap of DNA 
methylation values across a combined set of the Heidelberg fresh-frozen 
cohort and the FFPE tumour cohort (n = 276). Patient age and copy-
number events derived from the 450k array data are indicated below 
the heatmap. g Correlation of DNA methylation values from a dilution 
series of fresh-frozen and FFPE tumour DNA from a single sample. 
h Copy-number plot of a Group 3 medulloblastoma from the FFPE 
series, showing stereotypic MYC amplification and i(17q). i Copy-num-
ber plot of an SHH medulloblastoma from the FFPE series displaying 
evidence of dramatic structural changes, reminiscent of chromothripsis
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were run in an entirely separate facility (Toronto cohort, 
n = 60). SNP genotyping from the array indicated that four 
samples were also part of the Heidelberg frozen cohort. As 
with the frozen versus FFPE comparison, the correlation 
between these paired samples run in different facilities was 
higher than any other pairwise comparison (mean Pearson’s 
correlation for paired samples, r = 0.988). The derived 
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again gave a very close overlap with the expression-defined 
subgroups (94.6 % concordance, Rand index = 0.86, 
p < 0.0001), showing the robustness of this platform for 
the classification of MB, independent of where the data are 
generated (Supplementary Figure 2a, b).
A further major benefit of using this comprehensive array 
platform rather than a targeted gene panel is the ability to 
generate genome-wide copy-number profiles using the inten-
sity measures of the methylation probes, with a good con-
cordance to other copy-number platforms such as CGH or 
SNP arrays, as we have recently described [14]. This allowed 
us to detect clinically relevant copy-number aberrations, such 
as MYC/MYCN/GLI2 gene amplifications, from the FFPE as 
well as the frozen tumour samples (Fig. 1f, h). Stereotypic 
MB copy-number changes showed the expected subgroup 
distribution (e.g. monosomy 6 in WNT tumours, 9q/10q loss 
in SHH, MYC amplification in Group 3, i(17q) in Group 
3/Group 4; Fig. 1f). For 66 samples from the Heidelberg 
cohort, copy-number data from whole-genome sequencing 
(WGS) were also available, and were assessed for the altera-
tions indicated in Fig. 1f. All scoring was consistent between 
WGS and 450k array profiles. Furthermore, 10/60 SHH-
MBs showed patterns of dramatic copy-number change, 
reminiscent of chromothripsis [13] (Fig. 1i). We have previ-
ously linked this phenomenon to TP53 mutations (typically 
germline) in SHH-MB [11]. This tool may therefore aid in 
identifying medulloblastoma patients with a particularly 
high risk of having underlying Li Fraumeni syndrome.
In summary, we demonstrate here a method for reliable 
classification of medulloblastoma into molecular subgroups, 
and tumour copy-number profiling, using a commercially 
available DNA methylation array platform that performs 
well on either frozen or FFPE tumour material. We also 
show that this technology can be reproducibly applied with 
low amounts of starting material, at different institutes, and 
with the benefit of easier handling compared with FFPE-
derived RNA. We therefore believe that this platform holds 
great potential for refining the information obtainable from 
large, archival tumour series. Most importantly, we also 
expect that this will become one of the key technologies 
for risk stratification and patient cohort selection in the next 
generation of large, biology-led, multi-centre clinical trials.
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